MA-LOADSPRING-SOLUTIONS
14.9.2022 19:31:33 CEST | Business Wire | Press release
LoadSpring Solutions, Inc., the enterprise market leader in project platform solutions, has accepted a strategic majority interest investment from Blattner Technologies. Blattner Technologies is on a mission to be the leading provider of Predictive TransformationTM services and tools in the data analytics, artificial intelligence, and machine learning industries.
LoadSpring’s partnership with Blattner Technologies aligns with our industry focus on digital transformation and advancing data usability, analytics, machine learning, and artificial intelligence. Blattner’s focus on AI and predictive technologies will help lead to our customers' next generation of advancement.
“Today’s investment announcement will enable LoadSpring to rapidly expand its vision of driving the project controls industry to a future where it aspires to be. This new partnership, including the additional board membership, will accelerate our platform development and AI/analytics technology innovation to enable faster geographic and industry expansion, truly unlocking LoadSpring’s potential. Together, our expertise in providing global cloud solutions for project-based organizations and our new partner's expertise in building companies will provide next-generation solutions for our customers,” states Eric Leighton, President and CEO of LoadSpring Solutions, Inc.
Blattner Technologies’ CEO Russ Blattner says, “LoadSpring has the resources and tools to complement the list of companies Blattner Technologies is acquiring in our mission to build a predictive transformation model that takes our customers from the basics of data management and analytics to operationalizing AI/ML and true predictive analytics throughout an organization.”
LoadSpring’s global office locations and executive management teams will remain in place, with Eric Leighton continuing in his leadership role as President and CEO. Blattner Technologies representatives Russ Blattner and John Leschorn, along with Terrance Berland, co-founder of Unicorn & Lion, LLC, will join the LoadSpring Board of Directors, providing operational and technology vision to drive customer solutions into the future.
“This investment combines secure technology infrastructure and next-generation tools and analytics to create a truly distinctive solution offering for customers. This is an industry trend that will continue as organizations better understand the power of controlling and mining their data and look for partners that can bring them complete solutions, not just pieces,” says Terrance Berland, a member of the Forbes Technology Council.
About Blattner Technologies
Nashville, TN Blattner Technologies – Building on a 115-year legacy of innovation by the Blattner family of companies, Blattner Technologies is on a mission to be the leading provider of Predictive TransformationTM services and tools in the data analytics, artificial intelligence, and machine learning industries.
About LoadSpring
Founded in 1999, LoadSpring is a global project management provider obsessed with offering advanced managed cloud services. LoadSpring delivers expert project management and control solutions, fast data and business intelligence access, and hundreds of best-of-breed project-based applications. Data safety is assured through SOC 2 Type II security certification, providing an impenetrable cloud environment. LoadSpring customers and partners get higher productivity and ROI through our proprietary project platform while reducing the burden on their IT departments.
For more information, contact Stacey Witt at switt@loadspring.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006196/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom